Targeting the Immune Microenvironment in the Treatment of Head and Neck Squamous Cell Carcinoma

Head and neck squamous cell carcinoma (HNSCC) is a highly aggressive solid tumor, with a 5-year mortality rate of ~50%. The development of immunotherapies has improved the survival of patients with HNSCC, but, the long-term prognosis of patients with recurrent or metastatic HNSCC remains poor. HNSCC...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hui-Ching, Chan, Leong-Perng, Cho, Shih-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6803444/
https://www.ncbi.nlm.nih.gov/pubmed/31681613
http://dx.doi.org/10.3389/fonc.2019.01084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6803444/
https://www.ncbi.nlm.nih.gov/pubmed/31681613
http://dx.doi.org/10.3389/fonc.2019.01084

Ejemplares similares